Ozempic and Birth Control: Why Semaglutide Has No OC Warning — Evidence Review

Searches for “Ozempic and birth control” almost always trace back to the well-publicized Mounjaro and Zepbound warning that requires a barrier contraceptive for 4 weeks after each tirzepatide dose escalation. That warning does not apply to Ozempic. Ozempic is semaglutide [1,8] — a different molecule than tirzepatide [3,4,7] — and the Ozempic label [1] contains no oral-contraceptive interaction language. The supporting clinical-pharmacology study (Kapitza 2015, n=43 healthy women)^[5] showed bioequivalence for ethinyl estradiol and only a small, clinically irrelevant change in levonorgestrel exposure when subcutaneous semaglutide was co-administered with a combined oral contraceptive. Wegovy [2] is the same semaglutide molecule and carries no warning either. Rybelsus (oral semaglutide) has the same molecule-level answer but a separate 30-minute fasting rule that affects all oral co-medications, contraceptive pills included [10]. Non-oral contraceptives (patch, ring, IUD, implant, Depo) bypass the GI tract entirely and are unaffected by any GLP-1.

The bottom line: Ozempic doesn’t have the tirzepatide interaction

The Ozempic prescribing information [1] is unambiguous on this point. Section 12.3 (Pharmacokinetics — Drug Interaction Studies) states verbatim:

Semaglutide does not affect the pharmacokinetics of orally administered medications to a clinically relevant degree … co-administration of a combined oral contraceptive (0.03 mg ethinylestradiol/0.15 mg levonorgestrel) with semaglutide did not change the exposure of ethinylestradiol to a clinically relevant degree.

Section 7 (Drug Interactions) of the Ozempic label does not list oral hormonal contraceptives. The Wegovy label [2] mirrors this language for the same reason — same active ingredient, same regulatory dataset. By contrast, the Mounjaro [3] and Zepbound [4] labels carry the warning in three separate sections (Section 5.2 Warnings and Precautions for Zepbound, Section 7.2 Drug Interactions, and Section 8.3 Females and Males of Reproductive Potential).

The Mounjaro/Zepbound warning explained (so you know what we’re NOT talking about)

The Mounjaro and Zepbound prescribing information both contain a verbatim instruction: advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation. Mounjaro Section 8.3 adds the mechanism — use may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. The FDA Clinical Pharmacology Review for Mounjaro NDA 215866 documented the underlying pharmacokinetics from study I8F-MC-GPGR: a single 5 mg tirzepatide dose co-administered with an oral combined contraceptive reduced ethinyl estradiol Cmax by 59%, norgestimate Cmax by 66%, and norelgestromin (the active progestin metabolite) Cmax by 55%. AUC reductions were smaller (20-23%) but the Cmax drop is what drives contraceptive failure concern. The dose-escalation clause exists because the gastric-emptying delay resets partially with each titration step.

Detailed coverage of the tirzepatide warning lives on its own page: Mounjaro/Zepbound + birth control: the FDA 4-week backup-contraception requirement explained. The rest of this article is about why semaglutide is in a different bucket.

Why Ozempic doesn’t have the same interaction (Kapitza 2015 PK data)

The regulatory basis for the absent OC warning on the Ozempic and Wegovy labels is Kapitza et al, J Clin Pharmacol 2015 [5]. Forty-three healthy women received a single oral dose of ethinyl estradiol 30 µg / levonorgestrel 150 µg under two conditions: at baseline (no semaglutide), and at steady-state semaglutide 1.0 mg subcutaneous weekly. The results:

Both 90% confidence intervals for ethinyl estradiol fell within the standard 0.80-1.25 bioequivalence window. The 20% levonorgestrel AUC increase is directionally the opposite of any contraceptive-failure concern (more progestin, not less). The FDA accepted this study as evidence that no backup-contraception warning was needed for semaglutide. The 2024 J Am Pharm Assoc review by Skelley, Swearengin, and York [6] reached the same conclusion: among approved GLP-1 receptor agonists, tirzepatide is the only one with a clinically significant effect on oral contraceptive bioavailability. The 2025 Min et al. comprehensive PK review [9] confirms this in the same terms.

Why the difference between semaglutide and tirzepatide?

Both drugs slow gastric emptying, but the magnitude differs. Tirzepatide is a dual GIP/GLP-1 receptor agonist [7] — the GIP component adds gastric-motility effects on top of the GLP-1 mechanism. The Coskun 2018 discovery paper [7] documents the dual-agonist structure; the Lau 2015 paper [8] documents the selective GLP-1 mechanism of semaglutide. The clinical readout: tirzepatide’s acute gastric-emptying delay, especially after the first dose and after each titration step, is large enough to blunt peak contraceptive-hormone absorption by more than 50% — semaglutide’s is not. This is not a class effect; it is a tirzepatide-specific effect with a regulatory paper trail going back to NDA 215866.

Wegovy = Ozempic = same molecule = same answer

Patients sometimes assume Wegovy must carry a different contraceptive warning because it is dosed higher than Ozempic (2.4 mg/week vs Ozempic’s 2.0 mg/week ceiling). It does not. The Wegovy prescribing information [2] Section 7.2 contains no oral-contraceptive warning and Section 12.3 contains the same Kapitza-derived bioequivalence statement as the Ozempic label. The higher Wegovy dose does not appear to produce a clinically meaningful additional gastric-emptying effect on contraceptive absorption beyond what was already characterized in the Ozempic 1.0 mg PK study. If a patient is switching between Ozempic and Wegovy (common, given supply dynamics and insurance coverage), the contraceptive answer is the same in both directions: no backup required.

Disambiguation of the semaglutide brand portfolio lives at Is Wegovy the same as semaglutide? Brand disambiguation and a side-by-side dose/indication comparison at Wegovy vs Ozempic evidence review.

Rybelsus oral semaglutide: separate 30-minute fasting issue

Rybelsus is the only oral GLP-1 currently available as semaglutide (a 14 mg max-dose oral tablet, formulated with the absorption enhancer SNAC). The molecule-level answer for Rybelsus is the same as Ozempic and Wegovy: no backup-contraception warning. But Rybelsus carries a separate administration constraint that affects co-administered oral medications — including oral contraceptive pills. Section 2.1 of the Rybelsus label [10] requires the tablet to be taken:

• on an empty stomach upon waking;
• with no more than 4 oz of plain water;
• at least 30 minutes before the first food, beverage, or other oral medication.

If a patient takes their combined oral contraceptive pill at the same time as Rybelsus, both drugs will end up in a stomach that is no longer empty — which can degrade Rybelsus absorption and, theoretically, alter the contraceptive pill’s absorption window. The standard prescriber fix is to take Rybelsus immediately on waking, then take the oral contraceptive at least 30 minutes later with breakfast. This is a timing/administration issue, not a pharmacological interaction; the underlying semaglutide-OC pharmacokinetic finding from Kapitza 2015 still holds. The Hauge 2021 [PMID 34289755] oral-semaglutide drug-interaction studies confirm the general pattern: oral semaglutide’s absorption is what gets disturbed by co-administration, not the co-administered drug’s.

Non-oral contraceptives: patches, rings, IUDs, Depo — no interaction with any GLP-1

Any contraceptive that is not absorbed through the gastrointestinal tract is outside the scope of the entire gastric-emptying mechanism. None of the Ozempic, Wegovy, Mounjaro, or Zepbound labels indicate any concern for these methods, and the Zepbound label explicitly states — hormonal contraceptives that are not administered orally should not be affected:

• Transdermal patches (Xulane, Twirla, Ortho-Evra) — weekly skin application, no GI exposure.
• Vaginal ring (NuvaRing, Annovera) — intravaginal absorption, no GI exposure.
• Depot injection (Depo-Provera) — intramuscular every 3 months, no GI exposure.
• Levonorgestrel IUDs (Mirena, Kyleena, Liletta, Skyla) and the copper IUD (ParaGard) — intrauterine local delivery, minimal systemic exposure.
• Contraceptive implant (Nexplanon) — subdermal etonogestrel, no GI exposure.
• Barrier methods (male/female condoms, diaphragm, cervical cap) — mechanical, no hormones.

For patients on tirzepatide who do not want to manage a 4-week backup window after each dose escalation, switching to any of the above methods is the clean fix. For patients on Ozempic or Wegovy who are simply worried about whether their existing contraceptive is still effective, no change is required.

Pregnancy + GLP-1: the 2-month washout rule

The contraceptive question and the pregnancy question are distinct. Even though Ozempic does not require backup contraception, the Ozempic and Wegovy labels both recommend discontinuing semaglutide at least 2 months before a planned pregnancy. The reason is pharmacokinetic, not contraceptive: semaglutide has a half-life of approximately 1 week, which means roughly 5 weeks of washout to clear >95% of the drug from circulation. The 2-month margin adds a safety buffer. Reproductive toxicity (reduced fetal weights, skeletal variations) was observed in rat and rabbit studies at exposures comparable to human therapeutic doses. The same 2-month washout applies to Mounjaro and Zepbound.

If pregnancy is detected on therapy, current clinical guidance is to discontinue the GLP-1 promptly and discuss with the prescribing clinician. Pregnancy registries are accumulating real-world data; the in-utero exposure literature is still thin. Deeper coverage of the GLP-1 fertility and pregnancy questions lives at GLP-1s in pregnancy, PCOS, and fertility: the women’s health evidence.

Quick reference: what to do, by scenario

FAQ

Related on Weight Loss Rankings

• Mounjaro/Zepbound + birth control: FDA 4-week backup-contraception requirement explained — the sister article covering the tirzepatide side of this question in detail.
• Wegovy vs Ozempic evidence review — same semaglutide molecule, different doses and indications.
• Is Wegovy the same as semaglutide? Brand disambiguation.
• GLP-1 medication list: full reference.
• GLP-1s in pregnancy, PCOS, and fertility.
• GLP-1 drug interaction checker (tool) — quickly screen any oral medication against the gastric-emptying-delay class effect.